Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4

Rhea-AI Summary

BioVie (NASDAQ: BIVI) will host an exclusive investor webinar on March 4, 2026 at 4:15 p.m. ET and a live Q&A with CEO Cuong Do. The presentation will review investigational drug bezisterim (NE3107) and orphan candidate BIV201, clinical progress, safety signals, and development plans.

Registration is free via RedChip and questions may be pre-submitted to BIVI@redchip.com or asked live.

Key Figures

Webinar date: March 4, 2026 Webinar time: 4:15 p.m. ET

2 metrics

Webinar date March 4, 2026 Scheduled BioVie investor webinar

Webinar time 4:15 p.m. ET Start time of investor webinar

Market Reality Check

Price: $1.26 Vol: Volume 98,182 is at 0.83x...

normal vol

$1.26 Last Close

Volume Volume 98,182 is at 0.83x the 20-day average of 117,615, indicating subdued trading ahead of the webinar. normal

Technical Shares at $1.26 are trading below the 200-day MA of $4.06 and sit 92.54% under the 52-week high of $16.90.

Peers on Argus

BIVI was down 2.33% while closely ranked biotech peers showed mixed moves (e.g.,...

BIVI was down 2.33% while closely ranked biotech peers showed mixed moves (e.g., NERV up 2.1%, BCTX down 3.92%), suggesting stock-specific trading rather than a unified sector move.

Historical Context

4 past events · Latest: Feb 12 (Neutral)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Feb 12	Conference abstracts	Neutral	-3.5%	Two bezisterim abstracts accepted for psychiatry conference presentations.
Jan 08	Clinical trial update	Positive	-3.7%	Completion of enrollment of 60 patients in Phase 2 SUNRISE-PD trial.
Nov 19	Investor webinar invite	Neutral	-4.2%	December 9, 2025 investor webinar covering bezisterim and BIV201 programs.
Sep 26	Investor webinar invite	Neutral	+3.3%	October 8, 2025 webinar with pipeline and partnership opportunity updates.

Pattern Detected

Recent BioVie news — including a positive Phase 2 enrollment update — has often been followed by negative 24-hour price reactions.

Recent Company History

Over the past several months, BioVie has highlighted clinical and visibility milestones, including SUNRISE-PD Phase 2 enrollment completion and psychiatry conference abstracts for bezisterim (NE3107). The company has also repeatedly used investor webinars to showcase bezisterim and BIV201. Despite these updates, 24-hour reactions after three of the last four announcements were negative, indicating a pattern of cautious trading even on seemingly constructive news. Today’s webinar invitation fits this ongoing investor-relations outreach theme.

Market Pulse Summary

This announcement highlights BioVie’s plan to use a March 4, 2026 webinar at 4:15 p.m. ET to update ...

Analysis

This announcement highlights BioVie’s plan to use a March 4, 2026 webinar at 4:15 p.m. ET to update investors on bezisterim and BIV201. Context from recent months shows a stream of clinical and conference milestones, plus prior webinars focused on the same assets. With the stock trading well below its $4.06 200-day MA and $16.90 52-week high, attention centers on how late-stage development progress and potential partnerships for these programs evolve.

Key Terms

orphan drug, fda-approved therapies, insulin resistance, neuroinflammation

4 terms

orphan drug regulatory

"He will also outline progress with BIV201, BioVie’s orphan drug candidate for patients..."

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fda-approved therapies regulatory

"cirrhosis and ascites, who are subject to life-threatening complications with no FDA-approved therapies."

FDA-approved therapies are medical treatments that the U.S. Food and Drug Administration has formally reviewed and authorized for specific uses after finding sufficient evidence of safety and effectiveness. For investors, approval is like a business license and safety inspection rolled into one: it clears the main regulatory hurdle to sell the product widely, reduces development uncertainty, and can unlock insurance coverage and predictable revenue streams.

insulin resistance medical

"small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer’s..."

Insulin resistance is a health condition in which the body’s cells stop responding well to insulin, the hormone that helps move sugar from the blood into cells for energy, so blood sugar stays higher than normal. For investors, it matters because rising rates of insulin resistance expand demand for drugs, tests, devices and care services, affect long‑term healthcare costs and productivity, and influence the outlook for companies focused on metabolic and chronic disease treatment.

neuroinflammation medical

"where it has shown encouraging signals of improved cognition, motor function, and reduced neuroinflammation..."

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

AI-generated analysis. Not financial advice.

CARSON CITY, Nev., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on March 4, 2026, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss BioVie’s investigational drug candidate bezisterim (NE3107), a first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer’s, Parkinson’s, and Long COVID, where it has shown encouraging signals of improved cognition, motor function, and reduced neuroinflammation across clinical studies.

He will also outline progress with BIV201, BioVie’s orphan drug candidate for patients suffering from cirrhosis and ascites, who are subject to life-threatening complications with no FDA-approved therapies. With multiple clinical programs potentially advancing into late-stage development, strong safety data, and multi-billion-dollar market opportunities, BioVie is positioned to deliver significant value creation as it approaches pivotal milestones and potential partnerships.

A live Q&A session with management will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/webinar/BIVI/81669806685

Questions can be pre-submitted to BIVI@redchip.com or asked online during the live event.

About BioVie, Inc.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.  

Forward-Looking Statements

This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.  

Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BIVI@redchip.com

Chuck Padala
Managing Director
LifeSci Advisors, LLC
chuck@lifesciadvisors.com

FAQ

When is the BioVie (BIVI) investor webinar and who will present?

The BioVie webinar is on March 4, 2026 at 4:15 p.m. ET with CEO Cuong Do presenting. According to the company, the session will be hosted by RedChip Companies and include a live Q&A with management following the presentation.

What topics will BioVie (BIVI) cover in the March 4, 2026 webinar?

BioVie will discuss investigational drug bezisterim (NE3107) and orphan candidate BIV201, plus clinical progress. According to the company, presenters will highlight safety signals, encouraging clinical signals and potential late-stage development plans.

How can investors register for the BioVie (BIVI) March 4 webinar?

Investors can register for free via the RedChip webinar page linked by the company. According to the company, registration is available at the RedChip URL and questions may be pre-submitted to BIVI@redchip.com.

Will BioVie (BIVI) accept live questions during the March 4 event?

Yes, a live Q&A will follow the presentation and attendees can ask questions online. According to the company, questions can also be pre-submitted to BIVI@redchip.com ahead of the webinar.

What clinical topics about bezisterim (NE3107) will BioVie (BIVI) highlight on March 4?

BioVie will highlight bezisterim's signals of improved cognition, motor function, and reduced neuroinflammation seen in clinical studies. According to the company, discussion will focus on inflammation and insulin resistance as therapeutic targets and safety data across programs.